ESMO Congress 2024

From research & discovery to clinical care, Tempus is advancing precision medicine through the practical application of artificial intelligence in healthcare. We are pleased to share our latest scientific and clinical research findings along with new AI-enabled technologies during the ESMO Congress 2024.

Schedule a meeting with us

Evening Reception

Thank you for your interest in our event. The event has concluded, and we are no longer accepting RSVPs. To learn more about Tempus or continue the conversation, please contact us here. We will connect you with the right team member.

Tempus AI & Technology

Stop by our booth to discover how we are leveraging AI and technology to advance precision oncology.

Don't miss the opportunity to see how Tempus is offering one platform for precision oncology by harnessing AI to drive innovation, improve inefficiencies and streamline workflows.

Poster Presentations

Poster Presentations

September 15, 2024

Time
9:00 - 17:00
(Presentation main slot 12:00 - 13:00)

Location
113P

Presenters
Wade Iams (Tennessee Oncology); Rotem Ben-Shachar (Tempus), et al.

The Association of Changes in Circulating Tumor Fraction and in Actionable Variant Allele Frequencies with Clinical Outcomes in Real World Diverse Cohort of Advanced Patients Treated with Tyrosine Kinase Inhibitors

This study evaluates the use of circulating tumor DNA (ctDNA) for monitoring treatment response in advanced solid tumor patients treated with tyrosine kinase inhibitors (TKIs). Using the Tempus xM ctDNA assay, patients were classified as molecular responders (MRs) or non-responders (nMRs) based on changes in ctDNA tumor fraction (TF). The majority of patients ( 69%) had targetable SNV/indels; 13 were MRs and 18 were nMRs. MRs had longer overall survival (no deaths during follow-up) thannMRs. Among patients with decreasing variant allele frequencies (VAF, n=21), patients that were MRs (n=12) had significantly longer survival compared to nMRs (n=9). The study suggests that ctDNA TF monitoring may be used clinically to monitor response to TKI therapy beyond targeted VAF monitoring alone and warrants further validation

Time
9:00 - 17:00
(Presentation main slot 12:00 - 13:00)

Location
79P

Presenters
Jyoti Patel (Northwestern); Rotem Ben-Shachar (Tempus), et al.

Comprehensive Genomic Profiling Provides Patients Access to Novel Matched Therapies in a Diverse Real World Cohort of Advanced Lung Cancer Patients

This study assessed adherence with guideline-recommended targeted therapy recommendations and the time from genomic sequencing to the initiation of targeted treatment in a diverse, real-world dataset of advanced NSCLC patients. Findings show that most oncologists utilized comprehensive genomic profiling (CGP) to identify and treat patients with guideline-recommended, variant matched targeted therapy, with adherence rates varying according to the variant. Notably, even patients that received CGP results prior to FDA approval of novel therapies, received matched therapy once they were included in guidelines.

September 16, 2024

live session

Time
11:05 - 11:15

Location
CN13

Presenters
Dale Shepard (Cleveland Clinic); Samantha Mallahan (Tempus), et al.

Impact of AI Clinical Trial Program on Screening, Matching, and Enrollment of Patients Over 6 Months

The Tempus AI TIME initiative streamlined large-scale patient screening and clinical trial matching, enhanced patient enrollment and access, and achieved an average of more than one consent per day over a six-month period. Utilizing AI for patient matching and accelerating trial activation is recommended to maximize clinical trial success.

Time
9:00 - 17:00
(Presentation main slot 12:00 - 13:00)

Location
580P

Presenters
Alberto Puccini (Humanitas Research Hospital, Humanitas Cancer Center,); David Foureau (Levine Cancer Institute, Charlotte), et al.

Impact of RAS and BRAFV600E Mutations on Tumor Immune Microenvironment and Associated Genomic Alterations in Patients with Microsatellite Instability (MSI) or DNA Mismatch Repair Deficient (dMMR) Colorectal Cancers

This study aimed to understand the impact of RAS and BRAF mutations on prognosis and treatment effects in MSI/dMMR patients in both localized and metastatic settings. These data suggest that MSI/dMMR colorectal cancers (CRC) with RAS mutations are less immunogenic and exhibit a lower tumor inflammatory profile in the tumor immune microenvironment (TIME) compared to those with RAS wild-type (RASwt) or BRAF V600E mutations. Further analysis and validation are required to confirm these findings.

Schedule a meeting with us

We'll be in touch shortly.